INTRODUCTION
Recently, we have characterized a new member of the insulin-like hormone superfamily, termed Ley I-L, which is specifically expressed in Leydig cells of the fetal and adult testis (1) and in the theca cells of the postnatal ovary (2) . The Ley I-L cDNA and gene were isolated from different mammalian species and characterized (1) (2) (3) (4) (5) . Sequencing revealed that the primary structure of the prepro-Ley I-L factor and exon-intron organization of the gene are more similar to those of preproinsulin and preprorelaxin than to those of preproinsulin-like growth factor I and II (1, 4) .
The Ley I-L gene is expressed at a high level in the adult testis and at a much lower level in the adult ovary. Analyses of Ley I-L transcripts in testis and ovary throughout the pre-and postnatal life of the mouse revealed a sexual dimorphic pattern of Ley I-L expression during development. No Ley I-L transcripts are detected in female embryos of any stage, whereas in male embryos transcripts are first detected at day 13.5. After birth, the level of Ley I-L transcription in testis remains constant during the first 3 weeks, increases at the time at which the first wave of round spermatids undergoes spermiogenesis, and reaches the highest level in adult testis. These results suggest that the Ley I-L peptide plays a role in germ cell maturation. In the female, expression of the Ley I-L gene is first detected in the ovary at day 6 after birth. This, taken together with the distinct expression pattern of Ley I-L during the estrous cycle and pregnancy, implies a functional role of Ley I-L during follicular development (5) .
As a first step in identification of the regulatory elements that control Ley I-L gene transcription and its cell-specific expression, we have cloned and sequenced the human, porcine, and mouse Ley I-L gene as well as their 5Ј-flanking sequences (4, 5) . Alignment of the 5Ј-flanking region of these genes did not reveal any significant sequence homologies. However, the TATA-box and two sequence stretches are conserved and located at equivalent positions in all three genes. The nucleotide sequence of one of the conserved sequences is identical to the consensus binding site for steroidogenic factor-1 (SF-1) (6), also designated as Ad4BP. SF-1, an orphan nuclear receptor, has been found to regulate several genes in testis, ovary, adrenal cortex, and pituitary gland (7) (8) (9) (10) (11) (12) (13) (14) (15) by binding to specific cis-acting elements in the regulatory region of these genes. The conservation of the consensus sequence of the SF-1-binding site in the 5Ј-flanking region of mammalian Ley I-L genes and the observation that SF-1 expression precedes the Ley I-L expression in testis and ovary suggests that SF-1 regulates the expression of the Ley I-L gene (5) .
In the present study, we demonstrate that SF-1 binds to the SF-1-binding sites in the Ley I-L promoter and transactivates the mouse Ley I-L promoter.
RESULTS

The Proximal 157-bp Region of the Ley I-L Promoter Is Required for Leydig Cell-Specific Transcription
To determine the region necessary for transcriptional regulation of the Ley I-L gene, MA10, LTK Ϫ , and F9 cells were transiently transfected with chloramphenicol acetyl transferase (CAT) constructs containing different lengths of the 5Ј-flanking region of the mouse Ley I-L gene obtained by progressive deletion (Fig. 1) . CAT activities were determined in cell extracts (Fig. 1) . For control experiments, these cell lines were also transfected with pSV40-CAT and pCAT basic.
The progressive removal of 5Ј-sequences of the Ley I-L gene from nucleotide position Ϫ2109 to Ϫ690 resulted in a slight increase of the promoter activity in MA10 cells. Further deletion of the sequence from Ϫ690 to Ϫ157 did not significantly affect the expression of the CAT reporter gene. However, a drastic decrease of CAT activity was observed when the sequence from Ϫ157 to Ϫ53 was deleted. These results suggest that the region between Ϫ157 to Ϫ53 of the Ley I-L promoter contains regulatory elements sufficient to direct the transcription of the reporter gene in the Leydig cells (MA10).
The cell type-specific activity of the Ley I-L promoter was demonstrated by measuring CAT activity in extracts of F9 and LTK Ϫ cells, which do not express Ley I-L (our unpublished data). No significant CAT activity was found in these cell lines, either transfected with p2109-CAT or with other constructs. These results demonstrate that the 5Ј-flanking region of the Ley I-L gene can direct the cell type-specific expression of the Ley I-L gene.
The Transcription Factor SF-1 Binds to the Ley I-L Promoter
As shown above, the region between bp Ϫ157 and Ϫ53 was determined to be sufficient for the regulation of the Ley I-L promoter in MA10 cells. DNase I footprinting analysis was carried out to identify the binding sites involved in the Ley I-L regulation. A DNA fragment spanning the region Ϫ157/ϩ4 was labeled at each strand and allowed to bind to MA10 nuclear proteins. In the experiments depicted in Fig. 2 , four protected DNA segments located between Ϫ43 to Ϫ37 (F1), Ϫ62 to Ϫ53 (F2), Ϫ110 to Ϫ102 (F3), and Ϫ142 to Ϫ130 (F4) were detected. The motif CCAAG-GCC in the protected site F2 was found to be conserved in sequence and located at an equivalent position in the mouse, porcine, and human Ley I-L gene and was identical to the consensus sequence C T CAAGG TT CC of the SF-1-binding site (5) . A further search of the nucleotide sequence in F1, F3, and F4 revealed that the sequences TCAAGGTC on the coding strand of F3 and TCACGGTC on the noncoding strand of F2 (Fig. 3) share homology with the consensus sequence of the SF-1-binding site. We named to the SF-1-binding site homologous sequences in the protected F2, F3, and F4 segment as an SF-1/1, SF-1/2, and SF-1/3 element, respectively. To examine whether the same nuclear protein binds to the sequence elements SF-1/1, SF-1/2, and SF-1/3 of the Ley I-L promoter, three oligonucleotides containing the sequences of SF-1/1, SF-1/2, and SF-1/3 sites were designed ( Fig. 3 ) and used in electrophoretic mobility shift assay (EMSA) (Fig. 4) . When the SF-1/1 oligonucleotide was incubated with the nuclear extracts of MA10 cells, one DNA/protein complex was observed ( The DNA/protein complex was further analyzed using an antibody inhibition assay with polyclonal antibodies directed against the purified bovine SF-1 (16). As shown in Fig. 4C , the SF-1-antiserum (lane 2) but not rabbit preimmune serum (lane 3) disrupted the formation of the SF-1/1 oligonucleotide-nuclear factor complex. EMSA was also performed with nuclear extracts of 15-day-old mouse testis, spleen, kidney, and MA10 cells. Binding of a nuclear protein to the SF-1/1 oligonucleotide was observed with nuclear extracts of MA10 cells and testis but not with extracts of spleen and kidney (Fig. 4D) , which do not express the SF-1 gene. These results confirm that the SF-1 protein is the component of the complex formed using the SF-1/1, SF-1/2, and SF-1/3 oligonucleotides.
SF-1 Transactivates the Ley I-L Promoter
The results of EMSA have demonstrated that SF-1 binds to the three SF-1 sites of the murine Ley I-L promoter. To examine whether the SF-1 can activate the transcription of the Ley I-L promoter by binding to the three sites and to establish the contribution of each of the three SF-1 elements to the promoter activity, a series of mutant reporter constructs were generated, in which one, two, or all three of the SF-1 elements were deleted (Fig. 5) . The constructs were introduced into MA10 cells, and the relative CAT activity was determined as a percentage of the activity of the wild-type p157-CAT construct. Transfection of the p157⌬SF-1/1-CAT with a deletion of 6 bp in the SF-1/1 site resulted in a reduction in promoter activity to 19% relative to the p157-CAT. A similar reduction in promoter activity was observed when the construct p100-CAT with progressive deletion of the sequence Ϫ157 to Ϫ101, was introduced into MA10 cells. A drastic decrease in CAT activity was observed with p100⌬SF-1/1-CAT, in which all three SF-1 sites were absent. The possibility that the reduction in CAT activity in the cell lysate transfected with p100-CAT was due to the absence of a further binding site in a deleted sequence (Ϫ157/Ϫ100) can be excluded, because the results of DNase I footprinting (Fig. 2) and EMSA (Fig. 4B, lane 7) with the oligonucleotide N1 spanning the nucleotide sequence between SF-1/2 and SF-1/3 sites failed to demonstrate a further binding site.
To examine more directly whether the SF-1 could transactivate the Ley I-L promoter, cotransfection experiments were performed in HeLa cells, which are known to lack the endogenous SF-1 protein (12) . The cotransfection of the p157-CAT together with the expression vector pRc/RSV did not result in CAT activity. However, cotransfection of the reporter construct p157-CAT with the expression vector pRSV/Ad4BP (17) , which encodes SF-1, resulted in a significant transactivation of the Ley I-L promoter in HeLa cells (Fig. 6) . 
DISCUSSION
In this report, we demonstrate that SF-1 binds to and activates the murine Ley I-L promoter. Cotransfection of a plasmid producing SF-1 with a Ley I-L-CAT reporter construct containing the sequence between Ϫ157 to ϩ4 of the Ley I-L gene into HeLa cells clearly demonstrates that SF-1 is required for activation of the Ley I-L promoter.
SF-1 was first recognized to regulate genes coding for steroidogenic enzymes in the adrenal gland and testicular Leydig cells (7, 8) . Recently, the arrest of gonadal development in SF-1-deficient mice (18) has led to the suggestion that SF-1 also activates other genes that are required for the differentiation of the reproductive system. It has been established that SF-1 regulates the specific expression of Mü llerian inhibitor substance (MIS) gene in Sertoli cells (12) and the genes coding for the ␣-subunit of LH and FSH (13) and for the ␤-subunit of LH in pituitary gonadotropes (14) . Because the Ley I-L gene is also regulated by SF-1 and Ley I-L deficient mice show a failure of outgrowth and differentiation of the gubernaculum, which is essential for testicular descent (our unpublished results), it is evident that the Ley I-L gene is involved in the SF-1-regulated gene cascade required for sexual differentiation.
Our analysis of the regulatory region of the Ley I-L gene revealed that the sequence from Ϫ157 to ϩ4 is sufficient for Leydig cell-specific transcription. DNase I footprint experiments revealed three protected segments between Ϫ157/Ϫ53 that contain DNA sequences homologous to the consensus SF-1-binding site. Deletions of these sequences led to a drastic decrease of the CAT activity in the MA10 cells. Antibody inhibition and competition assay indicated that each of the three SF-1-binding sites in the Ley I-L promoter possess equal binding affinities to SF-1. Moreover, transient transfection experiments in MA10 cells showed that mutant reporter constructs, in which the sequence for the SF-1/1-binding site or for both SF-1/2-and SF-1/3-binding sites were deleted, could be activated by SF-1 to a similar extent, approximately 17-19% of the wild-type construct. In conclusion, the three SF-1-binding sites in the Ley I-L promoter have (14) .
Furthermore, we demonstrated that SF-1 transactivates the Ley I-L promoter in cotransfection experiments in HeLa cells. Since SF-1 is able to activate the promoter of Ley I-L in HeLa cells, it is likely that transactivation occurs mainly via a direct binding of SF-1 to the three SF-1 binding sites, and that a cofactor or a ligand is not required for the transactivational properties of the SF-1 on the Ley I-L promoter. These data are consistent with previous reports that showed that SF-1 apparently activates rat LH␤ and salmon gonadotropin II␤ subunit genes in a ligand-independent manner (14, 19) . In contrast, the regulation of the MIS gene by SF-1 requires a SF1-specific ligand or a cofactor (12) . SF-1 by itself was unable to activate the MIS promoter in HeLa cells. Removal of the SF-1 ligand-binding domain enabled the truncated SF-1 to stimulate the MIS promoter in HeLa cells and led to the hypothesis that a cofactor specific for Sertoli cells was required for the SF-1 activation of the MIS gene. SF-1 is present in gonads, adrenal cortex, and brain, but the expression of certain SF-1-regulated genes is restricted to one of these organs. Therefore, other factors or SF-1 ligands must further distinguish gonadal from adrenal and brain-specific expression of SF-1-regulated genes. A synergistic interaction of SF-1 with other factors or a SF-1 cofactor specific for these organs may contribute to cell-specific and organ-specific expression of SF-1 responsive genes.
The pattern of Ley I-L expression during pre-and postnatal development of the testis and postnatal development of the ovary is correlated with the presence of SF-1 in these developmental stages. Marked differences were observed between the expression of Ley I-L and SF-1 in the testis during postnatal life. The amount of Ley I-L transcript increases after the third postnatal week and reaches its highest level in adult testis (5), whereas the level of SF-1 transcript drops slightly at postnatal day 15 and remains at a low level thereafter (12, 16) . These differences between relative expression of Ley I-L and SF-1 in postnatal testis could be explained by the presence of other transcription factors or hormonal influences that act in synergism with SF-1 to drastically enhance the expression of Ley I-L in adult testis. Such synergistic interactions have been observed between SF-1 and estrogen receptor in the regulation of the salmon gonadotrophin II␤ subunit gene in the pituitary gland (19) . In the mouse, serum levels of LH and FSH increase sharply between day 20 and 35 (20, 21) , precisely when Ley I-L expression increases. Therefore, transgenic experiments with reporter constructs containing the Ley I-L promoter may directly address whether the SF-1 binding sites are a key regulator of Ley I-L promoter activity in vivo as has been shown for the LH␤ (22) and MIS (23) genes and whether the increase of the Ley I-L expression in adult testis is the result of interactions between SF-1 and hormone-stimulated responses.
MATERIALS AND METHODS
Plasmid Construction
The 3.5-kb BamHI genomic fragment (5) containing the 5Ј-flanking region, exons 1 and 2 of the Ley I-L gene, was subcloned into pBluescript IIKS ϩ (pBam-1). A promoterless CAT basic vector (Promega, Madison, WI) and the genomic subclone (pBam-1) were used for preparation of the chimeric expression constructs (Fig. 1) .
Using the subclone pBam1 as a template, a fragment Ϫ690 bp/ϩ4 and Ϫ157/ϩ4 with an artificial HindIII site at the 5Ј-end and an XbaI site at the 3Ј-end was amplified by PCR and subcloned into the plasmid pCAT basic to produce p690-CAT and p157-CAT. The nucleotide sequence of these truncated clones was confirmed by sequencing. The p100-CAT was generated by digestion of p157-CAT with HindIII/ XhoI and religated. The HindIII/XhoI fragment Ϫ2109/Ϫ101 was isolated from the pBam-1 clone and ligated with the HindIII/XhoI-digested p157-CAT construct to create p2109-CAT. The p1361-CAT vector was constructed by digestion of the p2109-CAT construct with PstI and the Ϫ1361/ϩ4-CAT fusion fragment was purified from the agarose gel and subcloned by blunt-end ligation.
The vector p157⌬SF-1/1-CAT in which the conserved sequence CCAAGG (Ϫ61/Ϫ56) was deleted was generated by a two-step PCR-directed mutagenesis by the following procedures. First, a fragment Ϫ157/Ϫ41 was prepared using a 5Ј-HindIII site-GCACCTGGGAGAGGACTTC-3Ј as 5Ј-primer and 5Ј-CGCGCCGCCCATGGGCG GGAACACAGCCAA-3Ј as 3Ј-primer, and a fragment Ϫ63/ϩ4 was prepared using 5Ј-GCTGTGTTCCCGCCCATGGGCGGCGCGAGG-3Ј as 5Ј-primer and 5Ј-TGGTGGC AGGAGGCAGTGGGC-XbaI site-3Ј as 3Ј-primer. The p157-CAT construct was used as the template to amplify the two fragments. Subsequently, these two fragments were mixed and used for another round of PCR in the presence of the 5Ј-primer and the 3Ј-primer which have been used for amplification of the Ϫ157/Ϫ41 and Ϫ63/ϩ4 fragments, respectively. The final PCR product was digested with HindIII/XbaI, subcloned into a promoterless CAT vector, and the internal deletion was confirmed by sequencing. The p100⌬SF-1/1-CAT was generated by digestion of p157⌬SF-1/1-CAT with HindIII/XhoI followed by blunt-end ligation.
Cell Culture
The mouse fibroblast LTK Ϫ , mouse embryonic carcinoma F9 cells, and human HeLa cells were cultured in DMEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% heat-inactivated FCS (Boehringer, Mannheim, Germany) under 5% CO 2 . All media included penicillin (100 U/ml) and streptomycin (100 g/ml). The mouse tumor Leydig cell line MA10 was maintained as described (24) .
Transfection and CAT Assay
Mouse MA10, LTK Ϫ , and F9 cells were cotransfected with 10 g of the tested plasmid and 2 g of pCMV-␤-galactosidase control plasmid (CLONTECH, Palo Alto, CA) by the calcium phosphate coprecipitation method (25) . After exposure to the DNA precipitate for 12-16 h, cells were washed and fresh medium was then added. The cells were harvested 48 h later, and CAT activities were measured in the cell lysates (26) . One tenth of cell lysate was used to determine ␤-galactosidase activity. For each CAT reaction, cell extract was combined with 4 l of [ 14 C] chloramphenicol (Amersham, Arlington Heights, IL), 10 l of 20 mg/ml acetyl-coenzyme A (Sigma, St. Louis, MO), and 250 mM Tris, pH 7.8, to a final volume of 150 l. The mixtures were incubated at 37 C for 2 h, and the reactions were stopped by extraction with 1 ml ethyl acetate. Acetylated and nonacetylated chloramphenicol were separated by TLC.
Nuclear Extract
Nuclear protein extracts from MA10, LTK Ϫ , and F9 cells were prepared according to Dignam et al. (27) , whereas nuclear extracts from tissues were prepared by a modified method of Gorski et al. (28) . Briefly, 0.5-1 g of tissue was minced and homogenized in 10 ml homogenization buffer using a Teflon glass homogenizer. The homogenate was layered over 3.2 ml of homogenization buffer (10 mM HEPES, pH 7.3, 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 M sucrose, 2 g/ml leupeptin, 2 g/ml pepstatin A, 10% glycerol) and centrifuged in a SW40 rotor at 25,000 rpm for 30 min at Ϫ4 C. The pelleted nuclei were resuspended in 2 ml of nuclear lysis buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 2 g/ml leupeptin, 2 g/ml pepstatin A, 25% glycerol) and lysed using an all-glass Dounce homogenizer. The lysate was mixed for 30 min at 4 C and then centrifuged in a microcentrifuge at 12,000 rpm for 20 min at 4 C. The supernatant was dialyzed several hours against dialysis buffer (20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 2 g/ml leupeptin, 2 g/ml pepstatin A, 20% glycerol), frozen in liquid nitrogen, and stored at Ϫ70 C. The concentration of the nuclear proteins was measured by a protein assay kit (Bio-Rad, Richmond, CA).
EMSA
From the sequence around the three footprinted regions F2, F3, and F4, double-stranded DNA fragments were prepared by annealing of complementary oligonucleotides. The sequences of the sense strands of the double-stranded oligonucleotides were: SF-1/1: 5Ј-agcttTCCCGCCAAGGCCC-ATGG (Ϫ66/Ϫ49); SF-1/1 M: 5Ј-agcttTCCCGACAATTCC CATGG; SF-1/2: 5Ј-agcttACACAGCCCCTGACCGTGAC-TCG (Ϫ121/Ϫ99); SF-1/3: 5Ј-agctt GACTTCAAGGTC-CCAAGCTGGAC (Ϫ144/Ϫ122); N1: 5Ј-agcttCAAGCTGGA-CACACAG CCCC (Ϫ131/Ϫ112). The SF-1/1 M has three nucleotide substitutions in the consensus SF-1 binding site. The localization of the oligonucleotides within the promoter sequence are given in parentheses. Five nucleotides were added to the 5Ј-end of the synthetic oligonucleotides to use for labeling reaction with Klenow fragment and [␣-32 P]dCTP (Amersham). In each gel shift assay, 10 g nuclear extract were preincubated in a 20 l reaction mixture containing 20 mM HEPES, pH 7.9, 0.5 mM EDTA, 25 mM KCl, 25 mM NaCl, 0.5 mM dithiothreitol, 7% glycerol, and 2-4 g poly(deoxyinosinic-deoxycytidylic)acid. After 10 min, approximately 1 ϫ 10 4 cpm of 32 P-labeled probe was added, and the incubation was continued for 20 min on ice, then loaded onto 6% nondenaturing polyacrylamide gel. The gels were fixed in a solution of 10% acetic acid and 30% methanol, dried, and exposed to Hyperfilm-MP (Amersham). In competition assay, 100-fold excess of unlabeled double-stranded oligonucleotide was incubated for 15 min together with the nuclear extracts before addition of the 32 P-labeled probe. For antibody cross-reaction, 1 l of anti-SF-1 antibody (16) or rabbit preserum was incubated with the nuclear proteins for 30 min before addition of the 32 P-labeled probe.
DNase I Footprinting
The DNA fragments used for DNase I footprint analysis of the Ley I-L promoter were prepared from the p157-CAT construct by digestion of the plasmid with either XbaI or HindIII to label the coding and noncoding strand, respectively. Ends were filled in with [␣-32 P]dCTP using the Klenow fragment of Escherichia coli DNA polymerase I, and the fragments were subsequently released by XbaI or HindIII digestion as appropriate. In the binding reaction, 30-100 g MA10 nuclear extract and 5 ϫ 10 4 cpm of 32 P-labeled probe were used under the same conditions as in EMSA in a total volume of 100 l. The reactions were chilled on ice for 20 min. After the concentration of CaCl 2 had been adjusted to 2.5 mM, DNase I (3 U) was added, and the digestion was carried out at 20 C for 1 min. The reaction was terminated by adding 90 l of prewarmed (37 C) stop solution (20 mM Tris, pH 7.5, 20 mM EDTA, 0.4% SDS, 80 g/ml proteinase K, 80 g/ml yeast tRNA), and the probe was extracted with phenol-chloroformisoamylalcohol. The reaction products were precipitated and analyzed on a 6% sequencing gel along with a MaxamGilbert GϩA sequencing reaction as a size marker.
